JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alexoff, D. L.
Right arrow Articles by Volkow, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexoff, D. L.
Right arrow Articles by Volkow, N. D.
Journal of Nuclear Medicine Vol. 44 No. 5 815-822
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

Reproducibility of 11C-Raclopride Binding in the Rat Brain Measured with the MicroPET R4: Effects of Scatter Correction and Tracer Specific Activity

David L. Alexoff, BSE1, Paul Vaska, PhD2, Douglas Marsteller, MS3, Timofei Gerasimov1, Juan Li, MA4, Jean Logan, PhD1, Joanna S. Fowler, PhD1, Nicholas B. Taintor, MS2, Panayotis K. Thanos, PhD2 and Nora D. Volkow, MD2

1 Chemistry Department, Brookhaven National Laboratory, Upton, New York
2 Medical Department, Brookhaven National Laboratory, Upton, New York
3 Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York
4 Department of Applied Mathematics and Statistics, State University of New York at Stony Brook, Stony Brook, Stony Brook, New York

A new generation of commercial animal PET cameras may accelerate drug development by streamlining preclinical testing in laboratory animals. However, little information on the feasibility of using these machines for quantitative PET in small animals is available. Here we investigate the reproducibility of microPET imaging of 11C-raclopride in the rat brain and the effects of tracer-specific activity and photon scatter correction on measures of D2 receptor (D2R) availability. Methods: Sprague-Dawley rats (422 ± 29 g; n = 7) were anesthetized with ketamine/xylazine and catheterized for tail vein injection of 11C-raclopride. Each animal was positioned prone in the microPET, centering the head in the field of view. MicroPET data was collected for 60 min—starting at 11C-raclopride injection—and binned into 24 time frames (6 x 10 s, 3 x 20 s, 8 x 60 s, 4 x 200 s, 3 x 600 s). In 3 studies, 11C-raclopride was administered a second time in the same animal, with 2–4 h between injections. In a fourth animal, raclopride (1 mg/kg) was coinjected with 11C-raclopride for the second injection. Three rats received a single dose of 11C-raclopride. The range of doses for all studies was 6.11–18.54 MBq (165–501 µCi). The specific activity at injection was 4.07–48.1 GBq/µmol (0.11–1.3 Ci/µmol). Region-of-interest analysis was performed and the distribution volume ratio (DVR) was computed for striatum/cerebellum using sinograms uncorrected and corrected for scatter using a tail-fit method. Results: Test-retest results showed that the 11C-raclopride microPET DVR was reproducible (change in DVR = -8.3% ± 4.4%). The average DVR from 6 rats injected with high specific activity (<4 nmol/kg) was 2.43 ± 0.19 (coefficient of variation = 8%). The DVR for the blocking study was 1.23. The DVR depended on the mass of tracer 11C-raclopride injected for doses >1.5 nmol/kg. Scatter fractions within the rat head were ~25%–45% resulting in an average increase of DVR of 3.5% (range, 0%–10%) after correction. Conclusion: This study shows that the 11C-raclopride microPET-derived DVR is reproducible and suitable for studying D2R availability in the rat brain. MicroPET sensitivity was sufficient to determine reproducible DVRs from 11C-raclopride injections of 9.25 MBq (~250 µCi). However, the effect of tracer mass on the DVR should be considered for studies using more than ~1–2 nmol/kg raclopride, and scatter correction has a measurable impact on the results.

Key Words: microPET • rat brain • dopamine receptor • raclopride




This article has been cited by other articles:


Home page
Stem CellsHome page
J. A. Rodriguez-Gomez, J.-Q. Lu, I. Velasco, S. Rivera, S. S. Zoghbi, J.-S. Liow, J. L. Musachio, F. T. Chin, H. Toyama, J. Seidel, et al.
Persistent Dopamine Functions of Neurons Derived from Embryonic Stem Cells in a Rodent Model of Parkinson Disease
Stem Cells, April 1, 2007; 25(4): 918 - 928.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. K. Schiffer, M. M. Mirrione, and S. L. Dewey
Optimizing Experimental Protocols for Quantitative Behavioral Imaging with 18F-FDG in Rodents
J. Nucl. Med., February 1, 2007; 48(2): 277 - 287.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Casteels, P. Vermaelen, J. Nuyts, A. Van Der Linden, V. Baekelandt, L. Mortelmans, G. Bormans, and K. Van Laere
Construction and Evaluation of Multitracer Small-Animal PET Probabilistic Atlases for Voxel-Based Functional Mapping of the Rat Brain
J. Nucl. Med., November 1, 2006; 47(11): 1858 - 1866.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.